Not recommended
Human studies show no meaningful benefit, potential harm, or the risks outweigh any possible upside. Better alternatives exist.
Also known as: ma huang, ephedrine
Latest evidence update: 2025-12-19
Strongest in Study quality (74). Held back by Recency (0).
Solid mix of RCTs with some methodological gaps.
Few independent replications; results not yet robust.
Small combined sample; treat as preliminary.
Mixed direction across studies.
Mostly pre-2020 research; updates may be needed.
No quantified outcomes for Ephedrayet. Once the corpus has studies with measurable endpoints, you'll see per-outcome magnitude here.
Promotes modest weight loss of approximately 0.6-0.8 kg per month compared to placebo
Significantly increases the risk of gastrointestinal symptoms such as nausea, stomach upset, and digestive discomfort
Significantly increases the risk of psychiatric symptoms including anxiety, mood changes, and nervousness
Significantly increases the risk of heart palpitations and abnormal heartbeat sensations
Recommended: Banned in supplements
ProtocolEngine provides general health information based on published research. This is not medical advice. Consult a healthcare professional before starting any supplement or health protocol.
Significantly increases the risk of autonomic nervous system symptoms such as tremors, sweating, and rapid heartbeat